Production and separation of 230Pa for targeted alpha therapy applications utilizing progeny radionuclides 230U/226Th
Tara Mastren, Benjamin Stein, Gannon Parker, Valery Radchenko, Roy Copping, Mark Brugh, Christiaan Vermeulen, Francois Nortier, Eva Birnbaum, Kevin John, Michael Fassbender
Los Alamos National Laboratory, Oak Ridge National Laboratory
Oral Presentation
No conflicts of interest
Protactinium-230 (half-life 17.4 d) is the parent isotope of U-230 (half-life 20.8 d), a radionuclide of interest for targeted alpha therapy (TAT). Uranium-230 is of interest both directly and as the parent of Th-226 (half-life 30.6 m) another radionuclide of interest for TAT applications. Protactinium-230 can be made via the charged particle induced reactions 232Th(p,3n)230Pa and 232Th(d,4n)230Pa. These methods of production involve the separation of Pa-230 from a variety of fission products and bulk thorium in addition to the subsequent separation from U-230. Herein we report the production of Pa-230 from proton irradiated thorium targets and novel separation strategies employing sulfur-based extraction chromatographic resins.